Chromadex Corp (OQ:CDXC)

Business Focus: Biotechnology & Medical Research

Jul 09, 2020 06:36 am ET
ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model
ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen® (patented nicotinamide riboside) inhibits replication of a form of Coronavirus, the virus that causes COVID-19 infection, in mouse cells.
Jul 07, 2020 06:34 am ET
ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models
ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). This study will assess if administration of Niagen® (nicotinamide riboside, or NR) can reduce viral burden and inflammation in mouse and hamster models of COVID-19. ChromaDex’s patent-protected NR is a unique nutrient that supports cellular energy production and healthy mitochondrial function through efficient restoration of NAD+ levels. The study
Jun 30, 2020 06:32 am ET
New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen® (nicotinamide riboside or NR) in bolstering cellular health to counteract or reduce progression of numerous degenerative conditions. The proven ability of Niagen® to raise NAD+ levels was found to contribute to positive effects in preclinical models of aging, fertility, and circadian rhythms, and in a clinical study on liver function. Several of these studies were made possible through the global
Jun 17, 2020 06:33 am ET
ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation
ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world’s most respected quality management standard. This accreditation covers testing of the Company’s Tru Niagen® consumer products, its Niagen® ingredient, and phytochemical reference standards performed out of its quality control and R&D facility in Longmont, Colorado. The accreditation requires demonstration of full and continuous compliance with the most rigorous ISO quality standards, enabling ChromaDex to test and analyze its Tru Niagen® product, ingredients, and
Jun 16, 2020 06:32 am ET
ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference
ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 2:00pm ET (11:00am PT).
Jun 03, 2020 06:33 am ET
First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD)
ChromaDex Corp. (NASDAQ: CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the publication of a study evaluating the NAD metabolome in human liver samples from people with liver diseases including alcohol-related liver disease (ArLD). The study, published in
Jun 01, 2020 06:32 am ET
ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting
ChromaDex Corp. (NASDAQ:CDXC) announced today it has organized a virtual symposium entitled “Nicotinamide Adenine Dinucleotide (NAD+) in Human Health and Disease: The State of the Science on Nutrition Interventions” tomorrow Tuesday, June 2, from 8:30 to 10:00 AM EDT at NUTRITION 2020 LIVE ONLINE, the annual meeting hosted
May 27, 2020 06:32 am ET
ChromaDex to Participate in Panel on Master Files for Dietary Supplements Hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN)
ChromaDex Corp. (NASDAQ:CDXC) today announced its participation in a panel discussion titled “What New Dietary Ingredient Master Files Mean for Innovation & Compliance,” hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN). As the global leader in NAD+ science, ChromaDex maintains three New Dietary Ingredient (NDI) notifications from the Food & Drug Administration (FDA) for its proprietary Niagen® (nicotinamide riboside) ingredient and has obtained further regulatory approval in Canada, the European Union, and Australia.
May 21, 2020 06:32 am ET
ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition
ChromaDex Corp. (NASDAQ:CDXC) today announced Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa and ChromaDex Chief Scientific Advisor, was named the 2020 recipient of the Mary Swartz Rose Senior Investigator Award from the American Society for Nutrition (ASN) and its Foundation. This award, presented by ASN and supported by the Council for Responsible Nutrition (CRN), recognizes an investigator who has contributed outstanding research in the field of bioactive compounds for human health.
May 11, 2020 04:01 pm ET
ChromaDex Corporation Reports First Quarter 2020 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2020 financial results.
May 06, 2020 06:32 am ET
Ninth Published Human Trial on Niagen® Nicotinamide Riboside (NR) Shows Increase in NAD+ Levels, Additional Research Highlights Downfalls of Nicotinamide Mononucleotide (NMN)
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of several new studies, which have uncovered new clinical and preclinical findings for its Niagen® (nicotinamide riboside, or NR) cellular nutrient, paving the way for continued research. Through its industry leading research program, called the ChromaDex External Research Program (CERP), ChromaDex provides its patented nicotinamide riboside (NR, or Niagen) ingredient to research institutions and universities at no cost. ChromaDex continues to support NAD+ research and through CERP has developed a global community of esteemed
May 01, 2020 06:32 am ET
ChromaDex to Report First Quarter 2020 Financial Results on Monday, May 11, 2020
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Mon., May 11, 2020 at 4:30 p.m. ET to discuss its financial results for the first quarter ended Mar. 31, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
Apr 28, 2020 06:33 am ET
Cellular Health Market Leader Tru Niagen® to Launch in U.K. Online and in Retail Stores Exclusively with Superdrug, Expanding Global Retail Partnership Between ChromaDex and A.S. Watson Group
ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with A.S. Watson Group into Europe and launch of its flagship Tru Niagen® cellular health product online and in over 200 Superdrug stores across the Unit
Apr 23, 2020 06:32 am ET
ChromaDex and Watsons Launch New Tru Niagen® Beauty Cellular Nutrient in Hong Kong, Broadening Global Retail Partnership
ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its new Tru Niagen® Beauty cellular health and beauty daily supplement with Watsons Hong Kong, available online and in all Watsons stores in Hong Kong.
Apr 20, 2020 06:32 am ET
ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Ni
ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and innovators behind Niagen® (patented nicotinamide riboside) science, announced today the publication of results from preclinical research on cells and animal tissue infected with Coronavirus and a COVID-19 cadaver in the online scientific publishing website
Apr 14, 2020 06:32 am ET
Mar 23, 2020 06:30 am ET
Cellular Health Market Leader Tru Niagen® Launches Online in Australia
ChromaDex Corp. (NASDAQ:CDXC) announced today the e-commerce launch of Tru Niagen® in Australia with distribution partner Matakana Health Limited (MHL). Tru Niagen received its listing number on the Australian Registry of Therapeutic Goods (ARTG)...
Mar 12, 2020 04:44 pm ET
ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19
ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client, implying unsupported health claims about Tru Niagen and COVID-19. There are no published human...
Mar 10, 2020 04:01 pm ET
CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS
ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter 2019 financial results. “We delivered strong performance across key metrics in 2019, secured regulatory approval in the EU and Australia, and published the sixth human clinical...
Feb 27, 2020 06:30 am ET
New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model
ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the publication of a preclinical study in the journal Aging and Mechanisms of Disease,...
Feb 25, 2020 06:30 am ET
ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended Dec. 31, 2019. The financial results will be reported in a press...
Feb 12, 2020 06:30 am ET
ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science
ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of its flagship cellular health supplement Tru Niagen® (nicotinamide riboside) as a supplement offering in Nestlé Health Science’s (NHSc) personalized nutrition service – Persona Nutrition....
Feb 03, 2020 06:30 am ET
ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide
ChromaDex Corp. (NASDAQ:CDXC) today announced the expansion of its industry-leading reference standards business with a new line of cannabinoid (CBD) reference standards available to researchers across the globe.  These new materials are for...
Jan 15, 2020 06:30 am ET
ChromaDex Achieves New Regulatory Milestones in the European Union & Australia
ChromaDex Corp. (NASDAQ:CDXC) today announced regulatory authorizations to sell its patented nicotinamide riboside chloride (NR, or Niagen®) to consumers in both the European Union and in Australia. ChromaDex received its listing number for Tru...
Jan 06, 2020 06:30 am ET
First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
ChromaDex Corp. (NASDAQ:CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the...
Dec 16, 2019 06:30 am ET
ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®
ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded ChromaDex the 2019 “Best of Industry Award,” in the “Ingredient Supplier” category, for Niagen®...
Dec 11, 2019 06:30 am ET
ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide
ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of Tru Niagen® Pro 500, the largest daily serving of its patented nicotinamide riboside (NR, or Niagen®) ingredient in the world.  The product will be available exclusively through licensed...
Dec 05, 2019 06:30 am ET
ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New Zealand
ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with Matakana Health (MHL) until early 2023, which will now include Australia in its territory.  On Monday, ChromaDex announced the receipt of approval of nicotinamide...
Dec 02, 2019 06:30 am ET
ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA)
ChromaDex Corp. (NASDAQ:CDXC) today announced that it has received approval from the Australian Therapeutic Goods Administration (TGA) for its patented nicotinamide riboside chloride (NR) for use in listed complementary medicines.  The listing...
Nov 20, 2019 06:30 am ET
European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food
ChromaDex Corp. (NASDAQ:CDXC) today announced that European Member States have voted in favor of listing Nicotinamide Riboside Chloride (NR) as a novel food ingredient at a daily serving of 300mg for the healthy adult population. This approval...
Nov 12, 2019 04:01 pm ET
ChromaDex Corporation Reports Third Quarter 2019 Financial Results   
ChromaDex Corp. (NASDAQ:CDXC) today reported third quarter 2019 financial results. “We had another strong quarter with total net sales of $12.1 million, up 9% sequentially and 48% year-over-year,” said ChromaDex CEO Rob Fried. “In addition, we...
Nov 04, 2019 06:30 am ET
ChromaDex to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Nov. 12, 2019 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2019. The financial results will be reported in a press...
Oct 31, 2019 06:30 am ET
Tru Niagen® Wins ‘Most Favourite Brand’ Award Among Watsons Hong Kong Loyalty Members
ChromaDex Corp. (NASDAQ:CDXC) announced today its Tru Niagen® product was recognized as “MoneyBack Members’ Most Favourite Brand” at the Health, Wellness & Beauty Awards 2019 held in Hong Kong on October 24. The breakthrough cellular health product...
Oct 17, 2019 06:30 am ET
New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors
ChromaDex Corp. (NASDAQ:CDXC) announced today that the  results of a preclinical study conducted by Nestlé were published last month in the journal Nature Communications, a peer-reviewed open access scientific journal published by the Nature...
Oct 11, 2019 06:30 am ET
ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation
ChromaDex Corp. (NASDAQ:CDXC) issued the following statement. We would like to take this opportunity to comment on the latest order from the California court regarding the ongoing litigation with Elysium. This started as a breach of contract...
Oct 07, 2019 06:30 am ET
Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents
Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting supplements on the production of bioactive...
Sep 26, 2019 06:30 am ET
ChromaDex to Present at the 5th Annual B. Riley FBR Consumer and Media Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 5th Annual B. Riley FBR Consumer and Media Conference at the Sofitel Hotel in New York, NY....
Sep 10, 2019 08:00 am ET
Industry Leaders Aubrey De Grey And Frank Jaksch Join Yuva Biosciences Advisory Board
BIRMINGHAM, Ala., Sept. 10, 2019 /PRNewswire/ -- Yuva Biosciences, Inc., an anti-aging company developing cosmeceuticals as well as pharmaceuticals targeted at aging-associated hair loss, wrinkled skin, and reduced energy, today announced that Aubrey de Grey, Ph.D. and Frank L. Jaksch, Jr. have joined the Company's Advisory Board....
Aug 14, 2019 09:10 am ET
ChromaDex Announces $7 Million Private Placement of Common Stock
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a securities purchase agreement for the sale of $7.0 million of its common stock in a private placement. The private placement was led by new strategic investors. The private...
Aug 07, 2019 04:10 pm ET
ChromaDex Receives Positive Opinion on Nicotinamide Riboside as a Novel Food from the World-Leading European Food Safety Authority (EFSA)
ChromaDex Corp. (NASDAQ:CDXC) today announced that the European Food Safety Authority (EFSA) has issued a positive opinion on Nicotinamide Riboside (NR) as a novel food ingredient for use in a food supplement at a daily serving of 300mg for the...
Aug 07, 2019 04:01 pm ET
ChromaDex Corporation Reports Second Quarter 2019 Financial Results   
ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2019 financial results. “We successfully continue to build our global TRU NIAGEN brand and consequentially had another quarter strengthening our business momentum, economics...
Aug 06, 2019 04:05 pm ET
ChromaDex Adds Top Talent to its Leadership Team
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today three strategic hires to its executive team. Joining the company are Megan Jordan as Chief Communications...
Jul 31, 2019 04:05 pm ET
ChromaDex to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., August 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2019. The financial results will be reported in a...
Jul 24, 2019 06:30 am ET
TRU NIAGEN® Expands Canadian Retail Footprint with Distribution at Whole Foods Ontario Locations
ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru Niagen® (nicotinamide riboside) is now available in all seven Whole Foods Market locations across Ontario, in addition to select Pure Pharmacy locations, Fullscript...
Jul 23, 2019 06:30 am ET
ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board
ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed Brunie H. Felding, Ph.D., Associate Professor, Department of Molecular Medicine, Scripps Research Institute, California Campus, to the Scientific Advisory Board (SAB). ChromaDex CEO...
Jul 08, 2019 06:30 am ET
Newly Published Nicotinamide Riboside Study Further Demonstrates Safety of Sustained Niagen Supplementation and Optimal Dosing Levels
ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of its latest clinical study were published Friday in the journal Scientific Reports. The largest trial of nicotinamide riboside (NR) published to date, the new study further validates...
Jun 05, 2019 06:30 am ET
TRU NIAGEN® Awarded ‘Ingredient of the Year: Healthy Aging’ by NutraIngredients-USA
ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru Niagen® (nicotinamide riboside) received the ‘Ingredient of the Year: Healthy Aging’ award at the NutraIngredients-USA Awards in New Orleans on June 3, 2019. “We are...
May 15, 2019 04:01 pm ET
ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA....
May 09, 2019 04:01 pm ET
ChromaDex Corporation Reports First Quarter 2019 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2019 financial results. “Nutritional interventions that support cellular health, including boosting NAD levels with our product TRU NIAGEN®, are some of the most actionable steps consumers...
May 09, 2019 08:20 am ET
ChromaDex Announces $10 Million Issuance of Convertible Notes
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement.  The transaction was led by international strategic investors. The...
May 02, 2019 06:30 am ET
ChromaDex to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2019. The financial results will be reported in a...
Apr 24, 2019 06:30 am ET
ChromaDex Furthers TRU NIAGEN® Global Expansion in Canada with WELL Health Technologies
ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN® with Vancouver-based WELL Health Technologies Corp. (TSX.V: WELL) who intends on distributing TRU NIAGEN® via its partner network of pharmacy and other...
Apr 15, 2019 06:30 am ET
ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded eCommerce Distribution in Canada
ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen is now available in 36 Showcase stores in the...
Apr 09, 2019 06:30 am ET
New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)
ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen®) helps maintain heart function in mice by stimulating a conserved cellular response called the “mitochondrial unfolded protein response” (UPRmt
Apr 09, 2019 06:30 am ET
New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)
ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen®) helps maintain heart function in mice by stimulating a conserved...
Apr 03, 2019 06:30 am ET
Dr. Charles Brenner, Discoverer of Nutrient Nicotinamide Riboside as a Vitamin, Announced as Speaker at Upgrade XP’s Sixth Annual Biohacking Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world’s foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will speak at the Sixth Annual Biohacking...
Apr 01, 2019 08:40 am ET
Consolidated Research: 2019 Summary Expectations for Vishay Intertechnology, Belmond, Silicon Motion Technology, Ardmore Shipping, Northwest Pipe, and ChromaDex — Fundamental Analysis, Key Performance
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Vishay Intertechnology, Inc. (NYSE:VSH), Belmond Ltd. (NYSE:BEL), Silicon...
Mar 11, 2019 04:01 pm ET
ChromaDex to Present at the 31st Annual ROTH Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference at the...
Mar 08, 2019 06:30 am ET
ChromaDex Brings TRU NIAGEN® to SXSW® 2019
ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at SXSW®, as it marks the achievement of attaining over 160 research collaborations around the world on its patented NIAGEN® (nicotinamide...
Mar 07, 2019 04:01 pm ET
ChromaDex Corporation Reports 2018 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter and full year 2018 financial results. “Our momentum continues with another strong quarter, and a strong year overall.  In 2018, we successfully focused on the fundamentals, continuing...
Mar 01, 2019 06:30 am ET
ChromaDex to Present at the 39th Annual Cowen Health Care Conference
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39th Annual Cowen Heath Care Conference at the Boston Marriott Copley Place in Boston, MA....
Feb 28, 2019 06:30 am ET
ChromaDex to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., Mar. 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the fourth quarter ended December 31, 2018. The financial results will be reported in...
Jan 23, 2019 06:30 am ET
New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model
ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring physiological benefits to mothers and offspring. Conducted at the University of Iowa by Principal Investigator Dr. Charles Brenner, the Roy J. Carver Chair & Head of Biochemistry at the University of Iowa, as well as a founding co-director of the University of Iowa Obesity Initiative and Chief Scientifi
Jan 23, 2019 06:30 am ET
New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model
ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring...
Jan 22, 2019 04:05 pm ET
ChromaDex Prepared to Proceed with Patent Infringement Action Against Elysium Health
ChromaDex Corp. (NASDAQ:CDXC) today reported the rejection of Elysium Health Inc.’s challenge to Claim 2 of U.S. Patent No. 8,383,086 ("the '086 patent") by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office....
Dec 20, 2018 04:05 pm ET
ChromaDex Corp. and Nestlé Health Science Enter Global Commercial License and Supply Agreement for TRU NIAGEN®
ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a license and supply agreement with Nestlé Health Science (NHSc), a global leader pioneering quality science-based nutritional health solutions. The agreement provides NHSc the exclusive...
Dec 17, 2018 06:30 am ET
TRU NIAGEN® Expands North American Footprint with Product Launch in Canada
ChromaDex Corp. (NASDAQ:CDXC) announced today it has officially launched TRU NIAGEN® in Canada, having received regulatory approval for sale by Health Canada. Directly from the innovators behind NIAGEN® (nicotinamide riboside), the product is now...
Dec 12, 2018 08:00 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Procter & Gamble, Qorvo, McDermott International, Chanticleer, ChromaDex, and Taubman Centers — New Research Emphasizes Economic Gro
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Procter & Gamble Company (NYSE:PG), Qorvo, Inc. (NASDAQ:QRVO),...
Dec 12, 2018 06:30 am ET
TRU NIAGEN® to be Featured at the American Academy of Anti-Aging Medicine Annual Meeting
ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature TRU NIAGEN® (Booth #6095) at the American Academy of Anti-Aging Medicine World Congress, a gathering of physicians, researchers, and healthcare practitioners from Dec. 13-15 in Las...
Nov 28, 2018 08:35 am ET
Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Move
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of OraSure Technologies, Inc. (NASDAQ:OSUR), Sierra Wireless, Inc....
Nov 28, 2018 06:30 am ET
ChromaDex to Present at the 11th Annual LD Micro Main Event
ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Co-Founder & Executive Chairman, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 11th annual LD Micro Main Event at the Luxe...
Nov 20, 2018 06:30 am ET
New TRU NIAGEN® Stick Packs Target New Audiences and Consumer Needs
ChromaDex Corp. (NASDAQ:CDXC) announced today the launch of TRU NIAGEN stick packs, offering a new delivery method of its revolutionary nicotinamide riboside ingredient to promote cellular energy and repair. The stick packs, which each provide...
Nov 07, 2018 04:01 pm ET
ChromaDex Corporation Reports Third Quarter 2018 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported third quarter 2018 financial results. “I’m encouraged by the progress we made in the third quarter and remain enthusiastic about the future, TRU NIAGEN continued to show dramatic growth and we are...
Nov 06, 2018 06:30 am ET
ChromaDex Appoints Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation, effective immediately. Roberts brings over 30 years of experience in scientific innovation and...
Oct 31, 2018 04:05 pm ET
ChromaDex to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., Nov. 7, 2018 at 4:30 p.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2018. The financial results will be reported in a...
Oct 30, 2018 06:30 am ET
TRU NIAGEN® Recognized as Best Product & Most Popular Brand at Health, Wellness & Beauty Awards 2018 of Watsons Hong Kong
ChromaDex Corp. (NASDAQ:CDXC) announced today its TRU NIAGEN® product was recognized as “The Best Scientific Innovative Anti-Aging Health Supplement” at Health, Wellness & Beauty Awards 2018 held by Watsons Hong Kong under A.S. Watson Group on...
Oct 25, 2018 06:30 am ET
 TRU NIAGEN® to be Featured at One-Day Medical School at Yale University School of Medicine
ChromaDex Corp. (NASDAQ:CDXC) announced today its TRU NIAGEN® (nicotinamide riboside) nutrient will be featured at the inaugural One-Day Medical School conference, hosted by The Department of Obstetrics, Gynecology and Reproductive Sciences at the...
Oct 24, 2018 06:30 am ET
TRU NIAGEN® Daily Serving Strengthened Under FDA’s NDI Notification
ChromaDex Corp. (NASDAQ:CDXC) announced today it has strengthened its flagship TRU NIAGEN® (nicotinamide riboside) nutrient to 150mg capsules, two per day. The more potent product will launch on truniagen.com, effective today. “We are pleased to...
Oct 22, 2018 06:30 am ET
Science Behind TRU NIAGEN® to be Featured at the World Mitochondria Society Meeting
ChromaDex Corp. (NASDAQ:CDXC) announced today that it will present the science behind TRU NIAGEN® (nicotinamide riboside) at the 9th World Congress on Targeting Mitochondria 2018 in Berlin, Germany, from Oct. 23-25. Frank Jaksch, ChromaDex...
Oct 18, 2018 07:55 am ET
Market Trends Toward New Normal in LSC Communications, Corindus Vascular Robotics, Sprouts Farmers Market, Luminex, ChromaDex, and CareDx — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LSC Communications (NYSE:LKSD), Corindus Vascular Robotics, Inc....
Oct 03, 2018 06:30 am ET
TRU NIAGEN® PRO to be Featured at the North American Menopause Society (NAMS) Annual Meeting
ChromaDex Corp. (NASDAQ:CDXC) announced today that it will highlight its new TRU NIAGEN® PRO product at the NAMS Annual Meeting 2018 in San Diego, CA, beginning today through Oct. 6. “Aging is so much more than skin deep—down to the cellular...
Oct 02, 2018 06:30 am ET
ChromaDex Appoints Yan Chu as Managing Director, Asia Pacific
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Yan Chu as Managing Director, Asia Pacific, effective today. Based in Singapore, Chu will lead the TRU NIAGEN® business for the region. Chu is joining ChromaDex from Comvita, an...
Sep 24, 2018 06:30 am ET
TRU NIAGEN® Earns NSF International’s Certified for Sport® Certification
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced its TRU NIAGEN product recently earned...
Sep 21, 2018 06:30 am ET
TRU NIAGEN® PRO to be Featured at the Academy of Integrative Health & Medicine Annual Conference
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced it will exhibit at the AIHM Annual...
Sep 20, 2018 06:30 am ET
New TRU NIAGEN PRO Launched for Expansive Distribution by Healthcare Practitioners
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced the launch of TRU NIAGEN PRO (60ct,...
Sep 18, 2018 06:30 am ET
ChromaDex and Dartmouth College File Patent Infringement Lawsuit Against Elysium Health
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today that ChromaDex, Inc. and Trustees of...
Sep 17, 2018 06:30 am ET
ChromaDex Announces Strategic Partnership for Aging Research with Jiangxi Government in China
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced a strategic partnership for healthy...
Sep 11, 2018 06:30 am ET
ChromaDex to Participate in “Conquering Aging” Briefing with Frost & Sullivan
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced its participation in Growth Innovation...
Sep 06, 2018 06:30 am ET
TRU NIAGEN® to be Highlighted at Vitafoods Asia 2018 in Singapore
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced it will exhibit at Vitafoods Asia...
Aug 30, 2018 06:30 am ET
ChromaDex Announces Participation at The 20th Annual Global Investment Conference in New York City September 5, 2018
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced it will be featured as a presenting...
Aug 29, 2018 08:30 am ET
ChromaDex to Present at the 7th Annual Liolios Gateway Conference on September 6, 2018
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, has been invited to present at the 7th Annual Liolios...
Aug 24, 2018 08:20 am ET
Recent Analysis Shows Global Brass and Copper, Ennis, ChromaDex, Caleres, Oil States International, and Chanticleer Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Global Brass and Copper Holdings, Inc. (NYSE:BRSS), Ennis, Inc....
Aug 09, 2018 04:01 pm ET
ChromaDex Corporation Reports Second Quarter 2018 Financial Results   
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today second quarter 2018 financial results....
Aug 08, 2018 06:30 am ET
ChromaDex to Launch TRU NIAGEN® in New Zealand with Retail Partner Matakana SuperFoods
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today the appointment of Matakana Superfoods...
Aug 07, 2018 06:30 am ET
ChromaDex and Watsons Expand TRU NIAGEN® Retail Partnership Through 2021
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today the expansion of its partnership with...
Aug 02, 2018 06:30 am ET
ChromaDex Sets Second Quarter 2018 Financial Results on Thursday, August 9, 2018
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, will hold a conference call on Thurs., Aug. 9, 2018 at...
Jul 11, 2018 06:30 am ET
Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and Shows Potential for Improvement in Liver Health
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a novel form of vitamin B3, at University of Copenhagen...
Jul 09, 2018 06:30 am ET
TRU NIAGEN® to be featured at the American Association of Naturopathic Physicians Annual Convention and the 2018 Healthy Aging Summit
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its flagship consumer product to help improve the aging process, TRU NIAGEN®, at the...
Jun 25, 2018 06:30 am ET
ChromaDex added to membership of US small-cap Russell 2000® Index
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today it was added as a member of the US...
Jun 19, 2018 08:00 am ET
Research Report Identifies ChromaDex, W.P. Carey, Rambus, Dynex Capital, Home BancShares, and Granite Construction with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ChromaDex Corporation (NASDAQ:CDXC), W.P. Carey Inc. (NYSE:WPC), Rambus,...
Jun 04, 2018 06:30 am ET
ChromaDex Appoints Lisa Bratkovich as Chief Marketing Officer
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Lisa Bratkovich as Chief Marketing Officer, effective today. Bratkovich is joining...
May 29, 2018 06:30 am ET
TRU NIAGEN® to be featured at the American Society for Nutrition's Annual Meeting
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its novel form of vitamin B3, TRU NIAGEN® (Booth #405), at the American Society for...
May 14, 2018 06:30 am ET
ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Professor Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial...
May 10, 2018 04:05 pm ET
ChromaDex Corporation Reports First Quarter 2018 Financial Results
ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today first quarter 2018 financial results. First Quarter 2018 Highlights vs. First Quarter 2017 Net...
May 03, 2018 06:30 am ET
ChromaDex Sets First Quarter 2018 Financial Results on Thursday, May 10, 2018
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, will report financial results for the first quarter of 2018 on Thurs., May 10, 2018. The Company’s financial results for...
May 01, 2018 06:30 am ET
ChromaDex Remains Confident Amidst Inter Partes Review (IPR) Procedural Changes
SAS Supreme Court decision regarding challenged claims in an IPR has no effect on U.S. Patent 8,197,807
Apr 25, 2018 08:30 am ET
Consolidated Research: 2018 Summary Expectations for RPX, Cotiviti, NN, Dynex Capital, ChromaDex, and Cogent Communications — Fundamental Analysis, Key Performance Indications
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RPX Corporation (NASDAQ:RPXC), Cotiviti Holdings, Inc....
Apr 23, 2018 04:05 pm ET
ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director
New Management Structure Further Fuels Strategic Evolution into Consumer-Focused Integrated Nutraceutical Company
Apr 05, 2018 06:30 am ET
TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress
Keynote Speaker, Dr. Rudolph E. Tanzi, will sign copies of his new book, “The Healing Self,” at the TRU NIAGEN booth
Mar 29, 2018 07:30 am ET
New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular Health
Findings from the University of Colorado, Boulder Study Suggest Future Studies Should Focus on the Therapeutic Potential for Blood Pressure and Vascular Health
Mar 08, 2018 04:01 pm ET
ChromaDex Corporation Reports 2017 Financial Results   
Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 Million
Mar 06, 2018 06:30 am ET
ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018
IRVINE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, has been invited to present at the 30th Annual ROTH Capital Partners...
Mar 02, 2018 06:30 am ET
ChromaDex Sets Fourth Quarter and Full Year 2017 Conference Call for Thursday, March 8, 2018 at 4:30 p.m. ET
IRVINE, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, will hold a conference call on Thursday, March 8, 2018 at 4:30...
Feb 27, 2018 07:40 am ET
New Research Coverage Highlights Orbital ATK, Imperva, Dave & Buster's Entertainment, Flagstar, W.R. Grace, and ChromaDex — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Orbital ATK, Inc. (NYSE:OA), Imperva, Inc....
Feb 20, 2018 06:30 am ET
Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
New Human Clinical Studies Will Investigate the Role of NIAGEN® Nicotinamide Riboside in Mitochondrial Biogenesis and Systolic Heart Failure
Feb 16, 2018 04:30 pm ET
ChromaDex Chairman Stephen Allen Will Retire from Board of Directors
IRVINE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age is announcing that on February 13, 2018, Steve R. Allen, the Chairman...
Feb 12, 2018 06:30 am ET
ChromaDex Corporation Reports Preliminary 2017 Results   
Fourth Quarter 2017 Net Revenues Expected to Increase by 69% to Approximately $7.5 Million
Feb 08, 2018 06:30 am ET
National Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s Disease
Results of the Collaborative Study Provide Strong Preclinical Support for Nicotinamide Riboside Research in Alzheimer’s Patients
Jan 24, 2018 06:30 am ET
ChromaDex to Present at the 3rd Annual NAD+ Summit
Chief Scientific Advisor of ChromaDex, Dr. Charles Brenner, Headlines Presentation “NAD+: What It Is, How We Lose It, and How To Boost It”
Jan 23, 2018 06:30 am ET
ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary
IRVINE, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Mark Friedman as General Counsel and Corporate Secretary, effective...
Jan 22, 2018 06:30 am ET
Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB)
ChromaDex’s patent portfolio covering its key ingredient in TRU NIAGEN® remains strong
Jan 08, 2018 06:30 am ET
ChromaDex and Watsons Expand Partnership with TRU NIAGEN™ Retail Launch in Singapore
After launching in Hong Kong in September, Watsons expands TRU NIAGEN™ retail distribution to Singapore
Dec 20, 2017 08:15 am ET
New Research Coverage Highlights W.R. Grace, ChromaDex, Pegasystems, Lennox International, Compass Minerals International, and Itron — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of W.R. Grace & Co. (NYSE:GRA),...
Dec 14, 2017 06:30 am ET
Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure
New Research Suggests the Protective Benefits of NR May Lead to a New Therapeutic Option in Human Heart Failure
Dec 08, 2017 06:30 am ET
Nicotinamide Riboside Shown to Improve Mitochondrial Energy Production and Memory in Alzheimer’s Disease Research
IRVINE, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that in research published in the journal Nature, Dr. Johan Auwerx showed that Alzheimer’s...
Dec 04, 2017 06:30 am ET
The promoting mechanism of TRU NIAGEN™ to be featured at the American Academy of Anti-Aging Medicine World Congress
A4M Senior Vice-President Joseph Maroon will give away signed copies of his book, “Square One, A Simple Guide to a Balanced Life” at the TRU NIAGEN™ booth
Nov 29, 2017 06:30 am ET
ChromaDex to Present at the 10th Annual LD Micro Main Event
IRVINE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that its Chief Executive Officer and Co-Founder, Frank Jaksch will present at the 10th...
Nov 09, 2017 04:05 pm ET
ChromaDex Reports Third Quarter 2017 Financial Results
- Company Reports Third Quarter 2017 Revenue of $6.1 Million, Up 55% Compared to Last Year -- Continued Progress on Building a Consumer Products Platform Around TRU NIAGEN™-
Nov 06, 2017 06:30 am ET
ChromaDex Announces $23 million Private Placement of Common Stock
Private Placement Led By High Profile Venture Capitalists and Strategic Investors
Nov 02, 2017 06:30 am ET
ChromaDex to Report Third Quarter 2017 Financial Results on Thursday, November 9, 2017
-Company Will Host Investor Conference Call on Thursday, November 9, 2017-
Aug 10, 2017 04:05 pm ET
ChromaDex Reports Second Quarter 2017 Financial Results
-Company Reports Revenue of $5.3 Million for Q2 2017-...
May 25, 2017 04:05 pm ET
ChromaDex Announces Closing of Second Tranche of the $25 Million Strategic Investment Led by Mr. Li Ka-shing
IRVINE, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the closing of the $16.4 million second tranche of the strategic investment of up to $25 million led by Hong Kong business leader Mr. Li Ka-shing....
Mar 16, 2017 04:10 pm ET
ChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34%
IRVINE, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the financial results for the year ended Dec. 31, 2016....
Feb 23, 2017 06:30 am ET
A Letter from the ChromaDex Chief Executive Officer
IRVINE, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- The following is issued on behalf of ChromaDex:...
Feb 21, 2017 06:30 am ET
ChromaDex to Showcase Premier Innovation and Brand-Elevating Science at Engredea 2017
IRVINE, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today it is bringing some of its top industry-advancing health and wellness products and services to booth #868 at Engredea 2017, taking place March 9-12 in Anaheim, CA. ...
Dec 01, 2016 06:30 am ET
ChromaDex to Present at the 3rd Annual Bernstein Consumer Summit on December 8, 2016
IRVINE, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will present at the 3rd Annual Bernstein Consumer Summit. The investor summit will be held on Dec. 7-8, 2016 at the New York Hilton Midtown in New York, N.Y....
Nov 10, 2016 04:05 pm ET
ChromaDex Reports Third Quarter 2016 Financial Results
-Company Reports Revenue of $21.2 million for first 9 months 2016 and is on track for another record revenue year-Company Reports Revenue of $5.0 million for Q3 2016-Accelerating trend of peer-reviewed research validating NR continued during Q3...
Nov 04, 2016 06:30 am ET
ChromaDex to Attend the Torrey Hills Capital 2nd Annual Emerging Growth Conference on November 11, 2016
IRVINE, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will attend the Torrey Hills Capital 2nd Annual Emerging Growth Conference. The investor conference will be held on Nov. 10-12, 2016 at the Hilton Del Mar in Del Mar, California....
Oct 27, 2016 06:30 am ET
ChromaDex Appoints Kurt Gustafson to its Board of Directors
IRVINE, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Kurt Gustafson has joined the Company’s board of directors. Mr. Gustafson will also serve as chair of ChromaDex’s audit committee....
Oct 24, 2016 06:30 am ET
Nicotinamide riboside (NR) plays a critical role in the most efficient path to cellular energy production
IRVINE, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition and pharmaceutical products, announced today that an additional study recently published in the prestigious journal, Nature Communications, explains why NAD+ precursors (boosters) NR and nicotinamide mononucleotide (NMN) demonstrate similar metabolic benefits in mammals. The study conducted by a team including leading NAD+ researche...
Oct 10, 2016 06:30 am ET
Published studies in humans and mice reveal how a superior vitamin B3 may play an important role in helping us enjoy longer, healthier lives
IRVINE, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that results from three studies, including its first human clinical trial, have been collectively published in the prestigious journal, Nature Communications....
Oct 03, 2016 06:30 am ET
ChromaDex Adds New AnthOrigin™ to Its Proprietary Ingredient Portfolio
IRVINE, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has added its new AnthOrigin™ naturally extracted anthocyanins (≥15%) product to its portfolio of industry-leading health and wellness ingredients....
Sep 22, 2016 06:30 am ET
Leading Supplement Retailer Features NIAGEN® as Their Hot Ingredient for Fall, 2016
NR and NAD+ gaining more attention as consumers continue to look for ways to rejuvenate their energy IRVINE, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced leading supplement retailer, Vitamin Shoppe, featured NIAGEN® nicotinamide riboside (NR) in their Hot Ingredient Spotlight section in the Fall 2016 print edition of their Amazing Wellness maga...
Sep 15, 2016 04:56 pm ET
Update: ChromaDex will demonstrate how it’s raising the bar on ingredient technology, applications innovation and raw materials testing at SupplySide West 2016
IRVINE, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it will showcase a number of industry-advancing health and wellness products and services during this year’s SupplySide West, October 4 through 8 in Las Vegas. Attendees stopping by booth #P137 will see live demonstrations and explore exciting new ingredients, including the new Ant...
Sep 15, 2016 06:30 am ET
ChromaDex will demonstrate how it’s raising the bar on ingredient technology, applications innovation and raw materials testing at SupplySide West 2016
IRVINE, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it will showcase a number of industry-advancing health and wellness products and services during this year’s SupplySide West, October 4 through 8 in Las Vegas. Attendees stopping by booth #1420 will see live demonstrations and explore exciting new ingredients, including the new Ant...
Aug 30, 2016 06:30 am ET
ChromaDex to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016
IRVINE, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will present at the Rodman & Renshaw 18th Annual Global Investment Conference. The investor conference will be held on Sept. 11-13, 2016 at the Lotte New York Palace Hotel in New York, N.Y....
Aug 15, 2016 06:30 am ET
U.S. FDA issues GRAS No Objection Letter for NIAGEN®
IRVINE, Calif., Aug. 15, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that the U.S. Food and Drug Administration (FDA) has issued a generally recognized as safe (GRAS) No Objection Letter, in response to the NIAGEN® nicotinamide riboside chloride (NR) GRAS filing, Notice No. GRN 000635....
Aug 11, 2016 04:10 pm ET
ChromaDex Reports Record Revenue as Ingredients Sales Climb 83% Compared to Previous Year Period
IRVINE, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today record revenue for the second quarter ended July 2, 2016. ...
Aug 10, 2016 06:30 am ET
Scientists Find Important Clue to Restoring Muscle Function That’s Lost as We Age
Published study in mice points to the potential of a form of vitamin B3 referred to as NR to trigger this regenerative process  IRVINE, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that University of Pennsylvania researchers have uncovered an important clue as to why our muscles weaken as we age, and how NR (nicotinamide riboside)– when co...
Aug 02, 2016 06:30 am ET
ChromaDex to Report Second Quarter 2016 Financial Results on Thursday, August 11, 2016
IRVINE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its second quarter 2016 financial results on Thursday, August 11, after the close of the financial markets....
Jul 20, 2016 06:30 am ET
ChromaDex Clinical Trial Studying NIAGEN® Well Underway, With Eight Additional Collaborative Human Studies Active
IRVINE, Calif., July 20, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that the study of NIAGEN® - nicotinamide riboside is well underway having achieved 50% enrollment of its 140 total participants....
Jun 30, 2016 06:30 am ET
ChromaDex Vindicated by Retraction and Apology from Author of Misleading and Factually Inaccurate Article
IRVINE, Calif., June 30, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a leading provider of proprietary science-backed technologies and analytical services for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that an article by Bleecker Street Research published on Seeking Alpha on June 20, 2016 has been removed and replaced with an apology from the author....
Jun 28, 2016 06:30 am ET
ChromaDex Added to the Russell 2000® Index
IRVINE, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a leading provider of  proprietary science-backed technologies and analytical services for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today announced that the company has been added to the Russell 2000®, the Russell 3000®, the Russell Microcap® Index and the Russell Global Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opened on June 27, according to a final list of additions posted June 27, 20...
Jun 21, 2016 12:26 pm ET
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChromaDex Corporation - CDXC
NEW YORK, June 21, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ChromaDex Corporation ("ChromaDex" or the Company) (NASDAQ: CDXC). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Jun 21, 2016 11:17 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ChromaDex Corporation (CDXC)
NEW YORK, June 21, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ChromaDex Corporation ("ChromaDex" or "the Company") (NASDAQ: CDXC). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484....
Jun 20, 2016 06:40 pm ET
ChromaDex Responds to Short Attack
IRVINE, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans to respond to a report published today by an anonymous party on a stock-discussions website....
Jun 07, 2016 06:30 am ET
ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, William Smithburg, to its Board of Directors
IRVINE, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that William Smithburg has joined the Company's board of directors as an independent director. ...
Jun 06, 2016 06:30 am ET
ChromaDex Announces $5.25 Million Registered Direct Offering
IRVINE, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has entered into an agreement with one investor to purchase $5.25 million of the Company’s common stock in a registered direct offering. The fees associated with this transaction were minimal as no underwriter or placement agent was used in the offering....
Jun 01, 2016 06:30 am ET
University Researchers Show Vitamin Nicotinamide Riboside is an Effective Tool for Managing the Negative Effects of Obesity and Diabetes
IRVINE, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that researchers from the University of Iowa found a way to reduce the risks of developing insulin resistance and sensory neuropathy (nerve damage) in mice with induced prediabetes and type 2 diabetes, using ChromaDex’s nicotinamide riboside (NR), NIAGEN®, which is a form of vitamin B3...
May 25, 2016 06:30 am ET
ChromaDex to Present at the 2016 Marcum MicroCap Conference on June 1, 2016
IRVINE, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Financial Officer, Tom Varvaro, will present at the 2016 Marcum MicroCap Conference. The investor conference will be held on June 1-2, 2016 at the Grand Hyatt New York in New York, N.Y....
May 18, 2016 06:30 am ET
ChromaDex to Present at the 17th Annual B. Riley & Co. Investor Conference on May 26, 2016
IRVINE, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the 17th Annual B. Riley & Co. Investor Conference. The investor conference will be held on May 25-26, 2016 at the Loews Hollywood Hotel in Los Angeles, California....
May 16, 2016 06:30 am ET
ChromaDex Names Will T. Black to its Executive Team as Vice President, Sales and Marketing
IRVINE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Will Black has joined the company as Vice President of Sales and Marketing....
May 12, 2016 06:30 am ET
ChromaDex Reports Record Revenue and Quarterly Net Income as Ingredients Sales Climb 72%
-Company Records Net Income of $256,000 as Company Reports Record Revenue of $7.3 Million-...
May 10, 2016 06:30 am ET
ChromaDex to Report First Quarter 2016 Financial Results on Thursday, May 12, 2016
IRVINE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its first quarter 2016 financial results on Thursday, May 12, before the open of the financial markets....
May 05, 2016 10:00 am ET
Apr 28, 2016 06:30 am ET
ChromaDex to Present at the Drexel Hamilton Micro Cap Investor Forum on May 12, 2016
IRVINE, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the Drexel Hamilton Micro Cap Investor Forum. The investor forum will be held on May 12, 2016 at the offices of Drexel Hamilton in New York, New York....
Apr 13, 2016 10:05 am ET
Thorne Research Announces Clinical Study to Assess Nicotinamide Riboside on Brain NAD+ in College Football Players
NEW YORK, April 13, 2016 /PRNewswire/ -- Thorne Research and ChromaDex Corp. (OTCQX: CDXC) announced today a research endeavor with Mayo Clinic and the University of Minnesota Clinical and Translational Science Institute, regarding a planned clinical study to assess the effect of Nicotinamide Riboside (NR) on brain NAD+ in college football players. ...
Jan 21, 2016 10:14 am ET
NIAGEN® Launches at GNC Stores Nationwide
LIGHTHOUSE POINT, Fla., Jan. 21, 2016 /PRNewswire/ -- Specialty Nutrition Group, Inc. has announced the release of NIAGEN® in GNC stores nationwide, as part of its innovation partnership with the world's largest retailer of nutrition products.  NIAGEN® will be marketed under the F1RST® brand of patented and research-backed single-ingredient products in GNC stores....